FutureMeds is determined to shape the future of Decentralised Clinical Trials in Europe. After becoming the 1st DCT Site Network in Europe, the company has appointed Iwona Tongbhoyai as Chief Client Solutions Officer, in line with their objectives. In this pivotal role, Iwona will build further momentum and value for clients, partners and patients.
With the acquisition of emovis, the Berlin-based, dedicated study site and award-winning pan-European homecare visits and DCT solution provider, FutureMeds became the first DCT site network in Europe. And with it, a new opportunity arose within the organisation to influence the future of the company, drive progress and develop new solutions that can boost DCT adoption in Europe.
Due to her key contributions to the company’s growth, FutureMeds decided to promote Iwona Tongbhoyai to Chief Client Solutions Officer.
Besides being involved in all key growth projects expanding FutureMeds' client offering, in her new role, Iwona will be responsible for overseeing all Client Services, including Projects, Proposal & Feasibility, Quality, and providing support to FutureMeds growing Business Development team.
Additionally, Iwona takes on the responsibility of leading FutureMeds' Decentralised Clinical Trial strategy department, which will provide a new offering to our customers, partners and patients.
“At FutureMeds, we have achieved significant progress on our growth path and are now being acknowledged as a top-tier Site Network by our clients. Iwona, a valuable member of our Executive Team, has played a pivotal role in our success. I'm excited to broaden the horizons of her responsibilities. Our perspectives are very positive, and I have complete confidence in our team to continue driving our growth.”
- Dr Radoslaw Janiak, CEO at FutureMeds
In her new role, which blends strategic vision, client advocacy, and operational expertise, Iwona will be driving FutureMeds’ growth while ensuring clients are at the heart of every decision.
“While the clinical research landscape may seem complex, my mission is simple: listen intently, innovate purposefully, and amplify the voices of those who make clinical research possible."
- Iwona Tongbhoyai, Chief Client Solutions Officer
Iwona’s success in this role will be defined by:
Client Satisfaction: She aims to ensure improved product-market fit and that clients are consistently satisfied with the solutions provided and the service they receive.
Trial Solution Innovation: Working closely with clients, partners and research teams, she aims to drive the development and implementation of innovative solutions that address emerging client needs and challenges.
Operational Efficiency: Based on her operational background, streamlining processes and implementing best practices to optimise efficiency will remain a cornerstone of her role.
Team Development & Collaboration: She considers cultivating a strong, skilled team that's adaptable, empowered and can quickly respond to changing client demands a must.
Revenue Growth: Identify and capture new business opportunities, expanding the company's client base and increasing the lifetime value of existing clients.
Strategic Vision: Rallying cross-departmental teams under the flag of accelerating study start, First Patient In and improving study outcomes through collaborative, strategic solutions, is another cornerstone of her role.
Brand Enhancement: Enhancing FutureMeds' reputation as the most reliable and respected site network in Europe is her ultimate goal.
FutureMeds is the 1st European DCT Site Network, offering high traditional trial and DCT readiness across the whole network and home nursing solutions in 16 countries.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help speed up drug development and patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed large, qualified patient pools across Europe that enable faster patient enrolment, stronger retention and more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.